Biogen Inc. (0R1B.L)
0R1B.L Stock Price Chart
Explore Biogen Inc. interactive price chart. Choose custom timeframes to analyze 0R1B.L price movements and trends.
0R1B.L Company Profile
Discover essential business fundamentals and corporate details for Biogen Inc. (0R1B.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
17 Sept 1991
Employees
7.61K
Website
https://www.biogen.comCEO
Christopher A. Viehbacher
Description
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,800 full-time employees. The firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The firm's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
0R1B.L Financial Timeline
Browse a chronological timeline of Biogen Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 29 Oct 2025
Revenue estimate is $2.33B.
Earnings released on 31 Jul 2025
EPS came in at $5.47 surpassing the estimated $3.90 by +40.26%, while revenue for the quarter reached $2.65B , beating expectations by +12.88%.
Earnings released on 1 May 2025
EPS came in at $3.02 surpassing the estimated $2.90 by +4.14%, while revenue for the quarter reached $2.43B , beating expectations by +5.18%.
Earnings released on 12 Feb 2025
EPS came in at $3.44 surpassing the estimated $3.33 by +3.30%, while revenue for the quarter reached $2.45B , beating expectations by +6.98%.
Earnings released on 30 Oct 2024
EPS came in at $2.66 falling short of the estimated $3.77 by -29.44%, while revenue for the quarter reached $2.38B , missing expectations by -2.42%.
Earnings released on 1 Aug 2024
EPS came in at $4.00 , while revenue for the quarter reached $2.35B .
Earnings released on 24 Apr 2024
EPS came in at $2.70 , while revenue for the quarter reached $2.20B .
Earnings released on 31 Dec 2023
EPS came in at $1.71 , while revenue for the quarter reached $2.30B .
Earnings released on 30 Sept 2023
EPS came in at -$0.47 , while revenue for the quarter reached $2.53B .
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
0R1B.L Stock Performance
Access detailed 0R1B.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.